Biovica Secures Commercial Agreement with Leading NCI Cancer Center for DiviTum TKa Biomarker Test
Key Insights
Biovica has entered into a commercial client bill agreement with a leading U.S. NCI-designated Comprehensive Cancer Center for its FDA-cleared DiviTum TKa (search) blood-based biomarker test.
The agreement enables clinicians to order DiviTum TKa (search) for clinical use in breast cancer treatment monitoring, particularly for patients receiving CDK4/6 inhibitor therapy.
This partnership strengthens Biovica's position among leading academic cancer centers and provides a foundation for broader clinical and commercial expansion in the U.S. market.
Biovica International (search) announced it has entered into a commercial agreement with a leading U.S. NCI-designated Comprehensive Cancer Center, marking a significant milestone in the company's U.S. commercialization strategy for its FDA-cleared blood-based biomarker test, DiviTum TKa (search).
Commercial Partnership Expands Clinical Access
The client bill agreement enables clinicians at the institution to order DiviTum TKa (search) for clinical use in breast cancer treatment monitoring. The agreement streamlines ordering and billing processes while aligning with the cancer center's precision oncology initiatives. The adoption of DiviTum TKa improves access to treatment monitoring for patients receiving CDK4/6 inhibitor therapy and creates the foundation for potential stepwise expansion of clinical use over time.
"Entering into a commercial agreement with an NCI-designated Comprehensive Cancer Center of this caliber is an important step in our U.S. commercialization efforts," said Anders Rylander, CEO of Biovica. "The decision to adopt DiviTum TKa (search) in clinical practice confirms the clinical value of the test. The collaboration strengthens our position among leading academic cancer centers and provides a strong foundation for continued clinical and commercial expansion in the U.S."
Strategic Impact on Market Position
The agreement strengthens Biovica's presence among leading U.S. cancer institutions and establishes an additional reference institution for DiviTum TKa (search). This development supports increased confidence among clinicians and strengthens the company's dialogue with healthcare networks and payers, collectively paving the way for broader integration of the biomarker into clinical practice in the U.S.
About DiviTum TKa Technology
Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. The company's DiviTum TKa (search) assay measures cell proliferation by detecting the TKa (search) biomarker in the bloodstream. The assay has demonstrated its ability to provide insight into therapy effectiveness in several clinical trials.
The first application for the DiviTum TKa (search) test is treatment monitoring of patients with metastatic breast cancer. DiviTum TKa has received FDA 510(k) clearance in the U.S. and is CE-marked in the EU. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies as part of its mission to improve care for cancer patients.